Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including microglia; strongest in neutrophils | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 8 Parkinson's papers of 226 | 0.71 |
| pathways Reactome | 16 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 4351
Sealed predictions
- ARRB2 in dopamine neurons, braak-0.65 (p 0.058) → -0.20 (p 0.613)receipt 4359
- ARRB2 in microglia, braak-0.59 (p 0.095) → +0.21 (p 0.586)receipt 4358
Swarm cases
receipt 4359: ARRB2 in dopamine neurons, braak
- power
- full sample -0.45 (p 0.060, n 18), 95% CI -0.76 to +0.02. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.43 (p 0.075, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.52 (p 0.026, n 18). not the mix.
- skeptic
- leave-one-out range -0.56 to -0.38, sign flips 0; without severely affected donors -0.45 (p 0.060, n 18). robust.
- cell type
- strongest in OPCs: -0.60 (p 0.0086, n 18) vs -0.45 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ARRB2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ARRB2 · OPCs · braak: substantia nigra, an independent cohort (already registered)
receipt 4358: ARRB2 in microglia, braak
- power
- full sample -0.10 (p 0.696, n 18), 95% CI -0.54 to +0.39. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.09 (p 0.709, n 18). does not hold up.
- composition
- microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.05 (p 0.854, n 18). could be the mix.
- skeptic
- leave-one-out range -0.26 to +0.03, sign flips 1; without severely affected donors -0.10 (p 0.696, n 18). fragile.
- cell type
- strongest in OPCs: -0.60 (p 0.0086, n 18) vs -0.10 in microglia. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ARRB2 in microglia.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ARRB2 · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.18 p 0.534 (needs p < 4.5e-4)
Receipts
loading the receipts